![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://img.youtube.com/vi/wm4V0TcS1pc/0.jpg)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![PHASE II RANDOMIZED CLINICAL TRIAL COMPARING ROPEGINTERFERON VERSUS.... EHA Library. Barbui T. Jun 14 2020; 303391 PHASE II RANDOMIZED CLINICAL TRIAL COMPARING ROPEGINTERFERON VERSUS.... EHA Library. Barbui T. Jun 14 2020; 303391](https://library.ehaweb.org/image/abstracts/eha_2020/LB2602.jpg)
PHASE II RANDOMIZED CLINICAL TRIAL COMPARING ROPEGINTERFERON VERSUS.... EHA Library. Barbui T. Jun 14 2020; 303391
![Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms | Blood Cancer Journal Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-018-0048-9/MediaObjects/41408_2018_48_Fig1_HTML.jpg)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms | Blood Cancer Journal
![PDF) Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program PDF) Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program](https://i1.rgstatic.net/publication/349861081_Long-term_safety_and_efficacy_of_givinostat_in_polycythemia_vera_4-year_mean_follow_up_of_three_phase_12_studies_and_a_compassionate_use_program/links/6044668f92851c077f2126f1/largepreview.png)
PDF) Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://universitiamo.eu/app/uploads/edd/2018/08/IMG-20180824-WA0002.jpg)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![Facing erythrocytosis: Results of an international physician survey - Rumi - 2019 - American Journal of Hematology - Wiley Online Library Facing erythrocytosis: Results of an international physician survey - Rumi - 2019 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/767a0afe-7118-4d4e-94b4-dd0b672b7186/ajh25545-fig-0001-m.jpg)
Facing erythrocytosis: Results of an international physician survey - Rumi - 2019 - American Journal of Hematology - Wiley Online Library
![Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0040e851-1767-4678-a1d2-6a0253b632db/gr1_lrg.jpg)
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology
![Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6f6decec-32f9-4581-b839-c9be9b107269/ajh.v95.1.cover.jpg)
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://universitiamo.eu/app/uploads/2019/04/Schermata-2019-04-09-alle-11.12.21-700x350.png)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://universitiamo.eu/app/uploads/2018/07/lab-pavia-4.jpg)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1e371df3-38a5-4047-acde-d51a2cbbb92c/ajh25644-fig-0001-m.jpg)
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library
![The haematocrit and platelet target in polycythemia vera - Di Nisio - 2007 - British Journal of Haematology - Wiley Online Library The haematocrit and platelet target in polycythemia vera - Di Nisio - 2007 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/bb62d07f-fff9-4cf0-91b6-3f3a000ac101/bjh_6430_f2.gif)
The haematocrit and platelet target in polycythemia vera - Di Nisio - 2007 - British Journal of Haematology - Wiley Online Library
![Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5a555ed4-a3e5-4796-bb30-d91663e54a7f/gr3_lrg.jpg)
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology
![PDF) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia PDF) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia](https://i1.rgstatic.net/publication/6427109_Clinical_profile_of_homozygous_JAK2_617VF_mutation_in_patients_with_polycythemia_vera_or_essential_thrombocythemia/links/02e7e5253078511ec1000000/largepreview.png)